These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21771830)

  • 1. Discontinuation of aspirin for secondary prevention.
    Biondi-Zoccai G; Landoni G
    BMJ; 2011 Jul; 343():d3942. PubMed ID: 21771830
    [No Abstract]   [Full Text] [Related]  

  • 2. Aspirin for the primary prevention of vascular events?
    Morgan G
    Public Health; 2009 Dec; 123(12):787-8. PubMed ID: 19914670
    [No Abstract]   [Full Text] [Related]  

  • 3. [Low-dosage ASA should not be given as primary prevention. The risk is greater than the benefit--also in high risk of cardiovascular disease].
    Håkansson J; Hernborg A
    Lakartidningen; 2010 Feb 3-9; 107(5):260-2. PubMed ID: 20297567
    [No Abstract]   [Full Text] [Related]  

  • 4. Pravastatin and Aspirin.
    Armstrong PW; Lorell BH; Nissen S; Borer J
    Circulation; 2002 Aug; 106(6):e9011-2. PubMed ID: 12187915
    [No Abstract]   [Full Text] [Related]  

  • 5. The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.
    Tamargo J; Castellano JM; Fuster V
    Int J Cardiol; 2015 Dec; 201 Suppl 1():S15-22. PubMed ID: 26747390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation.
    Herlitz J; Tóth PP; Naesdal J
    Am J Cardiovasc Drugs; 2010; 10(2):125-41. PubMed ID: 20334450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose aspirin for primary prevention of cardiovascular disease.
    Bredie SJ; Wollersheim H; Verheugt FW; Thien T
    Semin Vasc Med; 2003 May; 3(2):177-84. PubMed ID: 15199480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Aspirin in cardiovascular prevention: does the approach differ by gender?].
    Temizhan A
    Anadolu Kardiyol Derg; 2007 Dec; 7 Suppl 2():2-4. PubMed ID: 18160359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. News of the polypill.
    Marshall T
    BMJ; 2008 Oct; 337():a2160. PubMed ID: 18936068
    [No Abstract]   [Full Text] [Related]  

  • 10. Why P is not perfect.
    Chopra V; Hayward RA
    Am J Med; 2012 Jun; 125(6):e1-2. PubMed ID: 22483057
    [No Abstract]   [Full Text] [Related]  

  • 11. Comments regarding "a systematic review of implementation of established recommended secondary prevention measures in PAOD".
    Lindahl AK
    Eur J Vasc Endovasc Surg; 2010 Jan; 39(1):87-8. PubMed ID: 19906546
    [No Abstract]   [Full Text] [Related]  

  • 12. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.
    Burger W; Chemnitius JM; Kneissl GD; Rücker G
    J Intern Med; 2005 May; 257(5):399-414. PubMed ID: 15836656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancing the science of aspirin in primary prevention of vascular events.
    Cardiovasc J Afr; 2007; 18(5):347-8. PubMed ID: 17985039
    [No Abstract]   [Full Text] [Related]  

  • 14. [The Primary Prevention Project Study Group. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice].
    De Caterina R
    Ital Heart J Suppl; 2001 Jun; 2(6):681-4. PubMed ID: 11460845
    [No Abstract]   [Full Text] [Related]  

  • 15. Aspirin in the secondary prevention of cardiovascular disease: an update of the APTC meta-analysis.
    Lièvre M; Cucherat M
    Fundam Clin Pharmacol; 2010 Jun; 24(3):385-91. PubMed ID: 19678849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combination drug improves adherence].
    Stiefelhagen P
    MMW Fortschr Med; 2016 Apr; 158(8):83. PubMed ID: 27116174
    [No Abstract]   [Full Text] [Related]  

  • 17. [Uncertain benefit of low dosage ASA in peripheral arterial disease. Low dosage in symptomatic--individual assessment in asymptomatic disease].
    Norgren L; Bergqvist D; Pärsson H
    Lakartidningen; 2010 Jun; 107(23):1534-5. PubMed ID: 20617774
    [No Abstract]   [Full Text] [Related]  

  • 18. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.
    Annemans L; Lamotte M; Kubin M; Evers T; Verheugt FW
    Int J Clin Pract; 2006 Sep; 60(9):1129-37. PubMed ID: 16939558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Epidemiology and prevention of cardiovascular diseases].
    Jánosi A
    Orv Hetil; 2005 Apr; 146(15):683-8. PubMed ID: 15895792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage study.
    Welin L; Wilhelmsen L; Björnberg A; Odén A
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1143-9. PubMed ID: 19672841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.